ESR1 and breast carcinoma: The results of our meta-analysis and the analysis of Bottini (2006) both suggested that the CR indicators (such as CR and cCR) were better for NCT than for NET in both HR+ and ER+ breast cancer patients, but the difference between combination therapy and monotherapy was not significant.